source
- Marea Therapeutics reports promising Phase 2b results for MAR001 in hypertriglyceridemiaMarea Therapeutics, which recently merged with oncology firm Lisata Therapeutics, disclosed data from the first part of its phase 2b trial of the drug candidate MAR001. The study enrolled patients…
- Rezera targets $181 million IPO to fund phase-3 trial of NLRP3 inhibitor for peripheral artery diseaseBoston-based biotech Rezera, which rebranded from NodThera last September, said it will seek an initial public offering to raise about $181 million. The proceeds are intended to move its brain-pene…